Related Experiment Videos
Hyperthermia and liposomal encapsulated doxorubicin
Rami Ben-Yosef1, Maya Gipps, Michael Zeira
1Radiobiology and Hyperthermia Laboratory, Radiotherapy Unit, Division of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. rby@tasmc.health.gov.il
The Israel Medical Association Journal : IMAJ
|July 5, 2003
Summary
Combined Doxil and hyperthermia (HT) shows promise in mice cancer treatment. Longer HT sessions (30 minutes) with Doxil significantly reduced tumor weight compared to shorter sessions or Doxil alone.
Area of Science:
- Oncology
- Pharmacology
- Biomedical Engineering
Background:
- In vitro studies suggest combined liposomal doxorubicin (Doxil) and hyperthermia (HT) is more effective than Doxil alone.
- This study investigates the efficacy of Doxil-HT in a murine tumor model.
Purpose of the Study:
- To evaluate the beneficial effect of Doxil-HT compared to Doxil monotherapy in mice.
- To determine the optimal duration for HT delivery in combination therapy.
Main Methods:
- Mice were inoculated with M/109 lung tumor cells.
- Doxil (8 mg/kg) was administered intravenously, followed by four HT sessions (5 or 30 minutes) over two weeks.
- Tumor volume and weight were measured five weeks post-injection.
Main Results:
- No significant difference in tumor volume or weight was observed between Doxil-HT5, Doxil-HT30, and Doxil alone groups initially.
- The Doxil-HT30 group showed a significant reduction in tumor weight compared to Doxil-HT5 and Doxil alone (P = 0.006 and 0.01, respectively).
- Tumor volume did not differ significantly across groups.
Conclusions:
- Combined Doxil-HT30 treatment demonstrates superior efficacy in reducing tumor weight compared to Doxil-HT5 and Doxil alone.
- Further research is needed to explore optimal time scheduling and temperatures for Doxil-HT therapy.